Whalesbook
Sector Tailwinds
India's healthcare sector continues to draw significant investor attention, fueled by robust FDI and private equity inflows. The industry offers defensive characteristics in a volatile global climate, supported by rising health insurance penetration and expansion into underserved Tier II and Tier III markets. Chronic diseases also contribute to sustained investor interest.
The structural growth of India's healthcare market is underpinned by increasing insurance coverage and a focus on expanding services into smaller cities. A growing burden of chronic diseases further solidifies the sector's appeal for long-term capital.
KIMS's Q2 Performance
Against this backdrop, Krishna Institute of Medical Sciences (KIMS) stands out as a tactical pick. The stock has corrected approximately 14% in the last three months. In the second quarter of fiscal year 2026 (Q2FY26), KIMS reported a strong 23% revenue growth. However, EBITDA declined by around 7% year-on-year, with margins softening to 21.5% from 28.5% a year ago.
This margin compression stems from the recent commissioning of several new hospitals that are still in their ramp-up phase and have yet to reach breakeven. Sub-optimal utilization and partial insurance empanelment at these new facilities are expected to keep margins subdued through Q3 and Q4 of FY26.
Future Growth Drivers
Management anticipates a significant recovery in margins and accelerated profitability from FY27 as these new hospitals mature. KIMS is strategically expanding its footprint, adding approximately 600 beds in the second half of FY26 and around 900 beds in FY27. This expansion will boost its total capacity to roughly 7,600 beds from the current 6,114. The company is also deepening its presence in Tier II/III markets and entering Tier I cities like Bangalore, Mumbai/Thane, and Hyderabad.
Beyond physical expansion, KIMS is enhancing operational efficiency, integrating advanced technologies, and building out high-value specialties including oncology and maternal care. Average Revenue Per Operating Bed (ARPOB) has seen substantial growth, rising about 40% in the last two years to approximately ₹42,000 in Q2FY26. The recent revision in CGHS rates is projected to further boost ARPOB by about 20% of the business from Q4FY26. Management targets ARPOB reaching ₹50,000 by FY27-28.
Valuation and Outlook
KIMS maintains strong cash flows and low leverage, ensuring financial flexibility for growth. The company expects EBITDA margins to rebound to between 27% and 30% within the next two to three years. Its current valuation, trading at approximately 22.8 times FY27 estimated EV/EBITDA, represents a discount to its historical average and peers. This makes the recent stock weakness an attractive entry point for long-term investors.